1286 studies found for:    Ovarian Cancer: Clinical Trials
Show Display Options
Rank Status Study
21 Terminated Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer;   Bowel Obstruction
Interventions: Drug: Cisplatin;   Drug: Paclitaxel
22 Active, not recruiting Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer;   Fallopian Cancer;   Peritoneal Cancer
Interventions: Biological: E39 peptide vaccine;   Other: Clinical tracking for disease progression/recurrence
23 Completed A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: ABT-888;   Drug: pegylated liposomal doxorubicin;   Drug: temozolomide
24 Recruiting ICON8: Weekly Chemotherapy in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Carboplatin;   Drug: Paclitaxel
25 Completed Assess Cancer in Ovarian Tumors With Biomarkers.
Condition: Ovarian Tumor
Intervention: Procedure: Blood Draw
26 Active, not recruiting Phase 1/2 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
Condition: Ovarian Cancer
Intervention: Drug: IMAB027
27 Completed Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor
Conditions: Platinum Refractory Epithelial Ovarian Cancer;   Primary Cancer of the Peritoneum;   Cancer of the Fallopian Tube
Interventions: Drug: Sunitinib;   Drug: SUNITINIB
28 Active, not recruiting Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Pimasertib once daily;   Drug: Pimasertib placebo;   Drug: SAR245409 placebo;   Drug: SAR245409;   Drug: Pimasertib twice daily
29 Recruiting A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Condition: Ovarian Cancer
Interventions: Drug: Niraparib;   Drug: Placebo
30 Recruiting CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Condition: Ovarian Cancer
Intervention: Biological: NYESO-1c259 T cells
31 Withdrawn CA-125 in Screening Patients at High Risk for Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Other: physiologic testing;   Procedure: study of high risk factors
32 Recruiting The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial
Condition: Ovarian Cancer (Epithelial)
Intervention: Radiation: involved-field radiation therapy
33 Terminated Clinical Trial for Ovarian Cancer (OvaRex®)
Condition: Ovarian Cancer
Intervention: Drug: oregovomab
34 Recruiting Phase II/III Trial of Maintenance Vigil™ for High Risk Stage III/IV Ovarian Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasms
Interventions: Biological: Vigil;   Biological: Placebo
35 Completed Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer
Conditions: Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Leukemia;   Liver Cancer;   Lymphoma;   Neuroblastoma;   Ovarian Cancer;   Psychosocial Effects of Cancer and Its Treatment;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: psychosocial assessment and care
36 Terminated
Has Results
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
Condition: Ovarian Cancer
Interventions: Biological: Abagovomab;   Biological: Placebo
37 Completed
Has Results
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Topotecan;   Drug: Pegylated liposomal doxorubicin (PLD);   Drug: BI 6727
38 Completed
Has Results
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Extraovarian Peritoneal Cancer;   Fallopian Tube Carcinoma
Intervention: Drug: Ontak
39 Active, not recruiting A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women
Condition: Epithelial Ovarian Cancer
Interventions: Procedure: CA125 assay on Abbott Architect i1000SR platform;   Procedure: HE4 assay on Architect i1000SR platform;   Procedure: Transvaginal Ultrasound
40 Active, not recruiting Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Conditions: Platinum Sensitive;   BRCA Mutated;   Relapsed Ovarian Cancer;   Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Drug: Olaparib 300mg tablets;   Drug: Placebo to match olaparib 300mg

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years